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Background: There is evidence to support the use of supplementation with long-chain omega-3 polyunsaturated
fatty acids (LCn-3PUFA) from oily fish or fish oil for the treatment of various inflammatory diseases such as
rheumatoid arthritis. Chronic obstructive pulmonary disease (COPD) is a progressive, terminal disease characterized
by persistent airflow limitation, lung and systemic inflammation. To date, one randomized controlled trial has been
published that assessed the efficacy of LCn-3PUFA in people with this condition. The aim of this article is to discuss
the feasibility of conducting a trial to evaluate fish oil supplementation as adjunct therapy in people with COPD.
Methods/Design: A 16-week parallel, double-blind, randomized, placebo-controlled dietary supplementation trial
will be evaluated. Forty participants meeting spirometric and clinical criteria for COPD will be recruited from
metropolitan Adelaide, South Australia. Participants will be randomized by minimization, based on a score derived
from the modified Medical Research Council Scale for breathlessness, to receive 6 g/day of fish oil (approximately
3.6 g/day of LCn-3PUFA), or placebo (6 g/day of corn oil) capsules. Feasibility outcomes (recruitment, retention,
supplement adherence, and time lost to exacerbation) and scientific outcomes (effect size and estimates of variance
for inflammatory biomarkers, incorporation of LCn-3PUFA into erythrocytes, small airways function, dyspnea and
functional exercise capacity) will be assessed pre- and post-intervention. Key feasibility criteria include recruitment
of 40 participants in 52 weeks, 75% participant retention rate, 2% increase in the proportion of long-chain omega-3
fatty acids in erythrocytes, and a positive moderate effect size in at least three efficacy measures.
Discussion: There are a number of challenges in designing supplementation intervention studies with this
population. These include the lack of prior data from which to select appropriate primary outcomes or to estimate
effect sizes, and the feasibility of continuous supplementation in a population characterized by multiple
comorbidities and a high likelihood of exacerbations, potentially requiring hospitalization or change in medication.
Upon completion of this protocol, feasibility outcomes will guide the direction of future multicentre dietary
interventions in this population.
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Chronic obstructive pulmonary disease (COPD) is a pro-
gressive lung disease characterized by irreversible airway
obstruction and systemic inflammation [1]. In 2008,
COPD was the fourth leading cause of death worldwide
[2], and is predicted to be the third leading cause of
death by 2030 [3]. Airway obstruction is caused by
inflammation of the bronchi leading to increased mucus
secretion (chronic bronchitis) and destruction of lung
parenchyma leading to distal airway dynamic compres-
sion (emphysema). Air flow is further limited by structural
changes that occur as a result of chronic inflammation [1].
The clinical signs and symptoms of COPD include dyspnea,
productive cough, wheeze, fatigue, reduced exercise toler-
ance and repeated respiratory infections. Exacerbations
(acute worsening of symptoms leading to a change in medi-
cation or management) caused by infection, change of sea-
son and air pollution, commonly occur in people with
COPD and contribute to the overall severity of the disease
[1]. The perception of breathing discomfort known as dys-
pnea, is one of the most common life impairing symptoms
of COPD [4]. Dyspnea restricts and reduces physical activ-
ity in people with COPD, which over time leads to a more
sedentary lifestyle, reduces cardiorespiratory fitness and
quality of life [4].
In people with COPD, both airway and systemic in-
flammation occur. It is unclear whether systemic inflam-
mation is pathological or results from an overflow of
inflammatory mediators from the lung [5]. Nonetheless,
the systemic inflammation associated with COPD can
impair skeletal muscle function and mass, cardiovascular
function, skeletal integrity and mental health, and there-
fore increase the risk of diseases such as osteoporosis,
cardiovascular disease, diabetes and depression [5-8].
Dietary interventions which have been shown to be
beneficial in the treatment of inflammatory diseases such
as rheumatoid arthritis and cardiovascular disease, such
as supplementation with long-chain omega-3 polyunsat-
urated fatty acids (LCn-3PUFA), might also be beneficial
for people with COPD.
Polyunsaturated fatty acids (omega-3 and omega-6)
are essential fatty acids that must be consumed in the
diet as the human body is unable to synthesize them.
They can be further desaturated and chain elongated to
form LCn-3PUFA or LCn-6PUFA, respectively. The
major LCn-3PUFAs, docosahexaenoic acid (DHA) and
eicosapentaenoic acid (EPA), can also be sourced directly
from consumption of fish, while the major long-chain
omega-6 fatty acid (LCn-6PUFA), arachidonic acid (AA),
can also be sourced through the consumption of meat,
dairy and eggs [9]. Both LCn-3PUFA and LCn-6PUFA
are essential for functions in multiple systems in the
body, but are particularly important in the inflammatory
response. The metabolism of omega-3 and omega-6 fattyacids have different effects in the body: EPA produces
less potent inflammatory eicosanoids than AA; EPA,
DHA and AA differ in their roles as mediators of inflam-
mation resolution [10]. Increased consumption of EPA
and DHA results in proportional increases of these fatty
acids in inflammatory cells at the expense of AA [11].
The production of inflammatory mediators is also
influenced by LCn-3PUFA at a cellular level through
changes in gene transcription. An important gene tran-
scription factor in the inflammatory response is nuclear
factor kappa beta (NF-κB), which must be activated before
it can translocate into the nucleus to commence gene
transcription [10,12]. It is suggested that DHA and EPA
are able to inhibit the activation of NF-κB, thereby redu-
cing the transcription of a number of inflammatory cyto-
kines and chemokines [10].
A preliminary review of the literature was conducted in
March 2013. Major databases with a health focus (for ex-
ample, Medline, Embase, Cochrane Library) and English
language clinical trial registries (for example, Clinical Trials.
gov) were searched for studies that investigated the intake
of polyunsaturated fatty acids (PUFAs) in human adults
with COPD. Conference abstracts were excluded. This
search identified five published studies and three study pro-
tocols (one of which is the proposed study); details of these
studies can be found in Table 1. An additional published
study was identified although the study has been retracted
due to falsified data and was therefore excluded [13].
{Broekhuizen et al. [14] investigated the effects of
PUFAs on the outcome of pulmonary rehabilitation (ex-
ercise capacity and reversal of muscle wasting). This
study compared the effects of eight weeks of pulmonary
rehabilitation combined with a total daily PUFA dose of
3.4 g/day (400 mg stearidonic acid, 760 mg gamma-
linolenic acid, 1,200 mg alpha-linolenic acid (ALA), 700
mg EPA and 340 mg DHA) versus a placebo (palm and
sunflower oils) in 102 people with COPD. All other in-
cluded published studies [15-18] investigated associa-
tions between omega-3 intake and COPD prevalence or
inflammation in different populations.
Overall the results of the five studies varied. Broekhuizen
et al. [14] reported an increase in maximum load (incre-
mental maximal test) and an increase in duration (fixed
load submaximal) bicycle ergometry tests for both groups;
however the increase in the PUFA group was significantly
greater than the placebo group. PUFA supplementation
had no effect on muscle strength or FEV1 and neither
PUFA supplementation nor pulmonary rehabilitation af-
fected biomarkers of inflammation [14]. McKeever et al.
[17] reported no significant association between LCn-
3PUFA and COPD. Both Shahar et al. [18] and Hirayama
et al. [16] reported inverse associations between LCn-
3PUFA intake and the prevalence of COPD, while de Batlle
et al. [15] reported negative associations between LCn-
Table 1 Summary of published studies and proposed trials of omega-3 fatty acid supplementation in chronic
obstructive pulmonary disease (COPD)
Author Broekhuizen
et al.
Shahar
et al.
McKeever
et al.
de Batlle
et al.
Hirayama
et al.
Barr
(Investigator)
Protocol
Engelen
(Investigator)
protocol
Proposed
study
Year 2005 1994 2008 2011 2010 2012
(recruiting)
2012
(recruiting)
2012
Country Netherlands United States Netherlands Spain Japan United States United States Australia
Study type Randomized
controlled
trial
Cross
sectional
Cross
sectional
Cross
sectional
Case
controlled
Interventional
pilot
Randomized
controlled trial
Interventional
feasibility
Retrospective/
prospective
Prospective Retrospective Retrospective Retrospective Retrospective Prospective Prospective Prospective
Sample size (n) 102 7,902 13,820 250 618 40-45 77 40
n with COPD 102 (100%) 197 (2.5%) 553 (4%) 250 (100%) 278 (45%) 40-45 (100%) Unclear 40 (100%)
Definition of
COPD
PBD, ≥ GOLD
stage 2 (at
least
50%≤FEV1
<80%
predicted)
FEV1 ≤65% ≥ GOLD
stage 2 (at
least
50%≤FEV1
<80%
predicted)
Not PBD
PBD FEV1/
FVC <0.70
PBD FEV1/FVC
<0.70
PBD FEV1/FVC
<0.70 and
PBDFEV1 <65%
predicted
PBD FEV1
<70%
predicted
PBD FEV1/FVC
<0.70
Mean Age (SD) A- 64 (10) 54 (6)e 42.2 (11.2) 68 (8) 65.8 (6)e N/A N/A N/A
P- 62 (8)
Mean PBDFEV1 %
(SD)
A- 38.2 (13.1) 90 (18)e Not reported 53 (16) Not reported N/A N/A N/A
P- 35.8 (15.1)
Intervention PUFA blendd No No No No Fish oil Fish oil Fish oil
Placebo Palm oil
(80%) &
sunflower oil
(20%)
No No No No Corn oil Olive oil Corn oil
Control group Yes No No No Yes Yes Yes Yes
Supplementation
duration
8 weeks N/A N/A N/A N/A 6 months (2g
EPA/ 0.5g DHA
per day)
4 weeks (3.5g
or 2.0g
omega-3
per day)
4 months
(3.4g omega-
3 per day)
Six-minute walk
test
No No No No No Yes No Yes
Bicycle ergometry Yes No No No No No No No
Pulmonary
function
Yes Yes Yes Yes Yes Yes No Yes
Blood biomarkers Yes No No Yes No Yes Yes Yes
HADS No No No No No No No Yes
Dyspnea
questionnaire
No No No No Yes No No Yes
QOL
questionnaire
No No No No No Yes No Yes
FFQ No Yes (61-item,
intake past
year)
Yes (178 item,
past years
intake)
Yes (122
item, past 2
years intake)
Yes (138 item,
past 5 years
intake)
No No Yes (74 item,
past years
intake)
Endothelial
function
No No No No No Yes No No
Muscle strength
(skeletal &
respiratory)
Yes No No No No No Yes No
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Table 1 Summary of published studies and proposed trials of omega-3 fatty acid supplementation in chronic
obstructive pulmonary disease (COPD) (Continued)
Muscle protein
synthesis &
breakdown
No No No No No No Yes No
Oxidative
capacity
No No No No No No Yes No
Duel-Energy X-ray
absorptiometry
No No No No No No Yes No
Statistical test Linear
regression
Logistic
regression
Nonlinear
regression
Logistic
regression
Logistic
regression
Association
between n-3
intake and
endothelial
function
Association
betweenn-3
intake and
protein
synthesis
ANOVA
Comparison
PUFA and
placebo
group after 8
week
intervention.
Association
between n-3
intake and
COPD
Association
between n-6
intake and
COPD
Association
between
PUFA and
biomarkers
Association
between PUFA
intake and
COPD
Results Greater ↑
exercise
capacity in
PUFA
compared to
placebo
group*.
COPD
strongly and
inversely
associated
with intake of
n-3 fatty
acids*b
No
association
between
COPD and n-
3 intake.
↑ ALA
associated
with↓ TNF-α
*a
↑ prevalence
COPD associated
with, ↓ PUFA
intake *b, ↓ n-6
intake *b, ↓ n-3
intake *b
N/A N/A N/A
↑ intake of
four of the n-
6 fatty acids
associated
with ↑ risk of
COPD*c.
↑ LA and AA
associated
with ↑ CRP
*c
PUFA no
effect on FEV1
or muscle
strength.
No change in
blood
biomarkers in
either group.
↑ AA
associated
with ↑ IL-6 *c
A, active; ALA, alpha linoleic acid; ANOVA, analysis of variance; AA, arachidonic acid; CRP, C-reactive Protein; FFQ, food frequency questionnaire; HADS, Hospital
anxiety and depression scale; LA, linoleic acid; n-3, omega-3 fatty acid; P, placebo; PBD, Post bronchodilator; PUFA, Polyunsaturated fatty acid; QOL, quality of life;
6MWD, six-minute walk distance.
*Statistically significant P <0.05 a odds ratio ˂1, bodds ratio ≥1.0, codds ratio ≥1.5.
PUFA refers to both omega-3 and omega-6 fatty acid intake.
d PUFA blend consists of 400 mg stearidonic acid, 760 mg gamma-linolenic acid, 1200 mg alpha-linolenic acid, 700 mg eicosapentaenoic acid and 340 mg
docosahexaenoic acid.
eWeighted mean.
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In studies that reported an association between intake of
omega-3 or omega-6 fatty acids and COPD, the strength of
the associations was predominantly small (odds ratio 1.5 to
3.5 [19]).
Excluding the current protocol, the search of the clin-
ical trials registries identified two randomized controlled
trials currently underway (University of Columbia [20]
and Texas A&M University [21]). The University of
Columbia study is a pilot randomized controlled trial with
a lower dose of LCn-3PUFA (2.5 g/day DHA + EPA) than
the proposed study, but for a longer supplementation
period. The Texas A&M University randomized controlled
trial has a similar dose to the proposed study (3.5 g/day
DHA + EPA) but for a shorter supplementation period (8
weeks). There are similarities between the three studies (for
example, outcomes and omega-3 dose) although the pri-
mary focus of the three proposed studies differs, with
Columbia University focusing on endothelial function,Texas A&M focusing on muscle repair and damage, while
the proposed study focuses on feasibility for a larger RCT.
In theory, LCn-3PUFA from fish oil may improve
efficacy of current treatments for COPD by reducing
inflammation. Given the paucity of data for fish oil
supplementation trials in people with COPD, there are
currently no data to guide study design decisions such
as appropriate outcome measures (including the pri-
mary outcome), likely effect sizes or sample size
determination. COPD is a complex condition where
comorbidities and exacerbations are to be expected,
both of which may confound the effect of, or adher-
ence to supplementation. In addition, slow recruitment
and high dropout rates have been reported in interven-
tion trials for people with COPD [22-24]. The driver
for this proposed research is the hypothesis that LCn-
3PUFA supplementation as an adjunct therapy will
improve health outcomes in people with COPD. How-
ever before this hypothesis can be tested, it is
Screening for 
eligibility and consent
Baseline assessments
(blood, pulmonary function, 
questionnaires, walk tests)   
Allocated 
to fish oil
Randomization
16-week 
supplementation
and symptom diary
Post intervention assessments 
(blood, pulmonary function, 
questionnaires, walk tests)   
Exit survey
Allocated 
to corn oil
Figure 1 Study overview.
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protocol and justification for continuing to a larger
study.
While the terms ‘pilot study’ and ‘feasibility study’ are
often used interchangeably in the literature, Arain et al.
[25] explains the distinction between the two. A feasibil-
ity study seeks to determine if the study is possible, with
the available resources and in the current circumstances.
A pilot study is used to determine the efficiency of the
study protocol as a whole. Thabane et al. [26] and van
Teijlingen et al. [27] recommend undertaking a feasibil-
ity study in order to determine recruitment rates, esti-
mate variability of outcomes to assist with sample size
calculations or to obtain data to support a funding
application.
Given the lack of pre-existing data on which to inform
primary outcome and sample size estimates and the
known complexities of undertaking intervention studies
in people with COPD, this study aims to determine the
feasibility of undertaking a randomized controlled study
of daily LCn-3PUFA supplementation in people with
COPD. The objectives of this study are to determine
feasibility within two domains including process (for
example, recruitment and retention rates) and scientific
(for example, estimate of effect size and variance in
outcomes).
Methods/Design
Study design
A 16-week parallel, double-blind, randomized, placebo-
controlled dietary supplementation trial will be conducted
in the Respiratory Medicine department at the Repatriation
General Hospital (RGH), Adelaide, South Australia in col-
laboration with the Nutritional Physiology Research Centre
(NPRC), University of South Australia, Adelaide, South
Australia and the Clinical Nutrition Research Centre,
University of Newcastle, Callaghan, NSW. Participants
will attend the RGH on two occasions (pre- and post-
intervention) for a series of tests including pulmonary
function, venepuncture, well-being questionnaires and
functional exercise capacity (see Figure 1).
Participants
Participants will be recruited from the respiratory
clinical trials database (which contains >500 people who
have previously indicated their willingness to be contacted
for future studies) at the RGH. To be eligible for inclusion,
participants are required to be adults (≥18 years of age),
have a clinical and spirometric diagnosis of COPD (FEV1/
FVC <0.7) based on GOLD criteria [1], and stable medica-
tion for 28 days prior to screening. Participants will be
excluded from the study if they habitually consume LCn-
3PUFA supplements, have unstable or very severe COPD
(FEV1 <30% predicted) [1], have a diagnosis of α-antitrypsin
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tional weight loss of >5% within 12 months [28] or have a
body mass index (BMI) ≤18.5 kg/m2), are morbidly obese
(BMI ≥40 kg/m2), are experiencing unstable comorbidities
(for example, right heart failure, sleep disorders), have used
systemic steroids or antibiotic medication within 28 days
prior to enrolment, are diagnosed with respiratory condi-
tions not related to airflow limitation (for example, pul-
monary fibrosis), have unstable medication use (change in
medication or use in the 6 months prior to enrolment),
have participated in a comprehensive pulmonary rehabilita-
tion program in the previous 2 years or are intending to
undertake this type of rehabilitation program in the 6
months following study enrolment. Written informed con-
sent will be obtained from all participants.
Ethics and Trial registration
Ethics approval for this study was granted by the Human
Research Ethics Committee of the University of South
Australia (project number: 0000026302) and Southern
Adelaide Clinical Human Research Ethics Committee
(project number: 208.12). The trial was registered on the
Australia and New Zealand Clinical Trials registry
(ANZCTR) on the 3rd of February 2012 (ANZCTR
Number: 12612000158864).
Sample Size
As this is a feasibility study designed to determine prag-
matic aspects of methodology, formal sample size calcu-
lations are not appropriate [26,29]. The target sample
size for the feasibility study is 40 participants. The target
sample is to allow sufficient precision to enable sample
size calculations for subsequent studies. Browne [30]
suggests that a minimum of 30 participants is required
to achieve sufficient precision, a recommendation sup-
ported by Lancaster et al. [31]. The target sample of 40
enrolled participants will allow completion of 30 sub-
jects, allowing for a 25% participant dropout rate. A key
feasibility criterion is the ability to recruit a target sam-
ple of 40 participants within 52 weeks.
Randomization
Subjects will be randomly allocated by minimization
[32,33], based on modified Medical Research Council
(mMRC) scale for breathlessness scores, to either the
fish oil group or the placebo group. The prognostic fac-
tor that will be considered in the minimization model
will be mMRC score (0, 1, 2, 3 or 4).
Dietary intervention
Participants will be required to take six 1 g capsules or-
ally per day for 16 weeks. The fish oil group will con-
sume capsules containing EPAX 6000 TG/N omega-3
concentrate (EPAX, Oslo, Norway). Each capsulecontains 600 mg of omega-3 fatty acids, which is speci-
fied to contain 200 mg of DHA and 300 mg of EPA. It
should be noted that while the recommended upper
limit of LCn-3PUFA is 3 g/day [34], a number of studies
have used higher doses (3.4 g/day to 6.6 g/day) without
any reported side effects [35,36]. The placebo group will
receive capsules that are identical in appearance
containing corn oil (predominantly comprised of lino-
leic, oleic and palmitic acids) (EPAX, Oslo, Norway). All
capsules are flavored to mask the taste and odor. Partici-
pants will continue their usual medical treatment
throughout the supplementation period. Self-reported
medication and supplement use will be collected pre-
and post-intervention.
Blinding
Capsules will be prepackaged into opaque containers
and labeled as A or B with the investigator details and
supplementation instructions. A staff member of the
NPRC external to the project will determine the
computer-generated randomization schedule. Capsules
will be securely stored and will be dispensed in opaque
containers by the clinical trials pharmacist at the RGH,
thus ensuring blinding of both the participants and
investigators.
Anthropometry
Height will be measured to the nearest 0.5 cm using a
wall-mounted stadiometer (Seca 240, Seca, Hamburg,
Germany) and mass will be measured to nearest 0.1 kg
using a calibrated digital precision scale (Wedderburn
DS-520, Weddernburn, Australia) at both assessment
visits. BMI will be calculated from these data as mass
(kg) /height (m)2.
Dietary intake
Total energy, macronutrient consumption, and micronu-
trient consumption will be estimated at baseline using a
74-item food frequency questionnaire from the Cancer
Council of Victoria, Australia [37]. The food frequency
questionnaire has been validated [38] for use in human
dietary intervention trials. The food frequency question-
naire will be repeated post-intervention to determine
whether there were any changes in diet throughout the
supplementation period.
Comorbid status
Comorbid status will be determined using two question-
naires: the Charlson index [39], which weights comorbid
diseases based on their association with mortality, and
the Rx-Risk comorbidity index [40], which uses drug
classifications to determine comorbid diseases. Both
have been included because there is no consensus on
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fore, the suitability of both indices will be assessed.
Feasibility outcomes and criteria
Within the four domains of feasibility (process, re-
sources, management and scientific) there are specified
outcomes in the process and resource domains that will
be assessed throughout the study against feasibility
criteria (see Table 2).
Process outcome measures
A number of process outcomes will be assessed through-
out the study including participant recruitment and
retention, supplement adherence, time lost to exacerba-
tion and participant experiences and perspectives about
participating in the study. Participant recruitment and
retention will be assessed descriptively by recruitment
and refusal rates, while retention will be determined by
the number of enrolled participants who complete the
study protocol.
Supplement adherence will be assessed in three ways.
Firstly, by determining changes from baseline to post-
intervention in the LCn-3PUFA content of erythrocytes,
as the LCn-3PUFAs are incorporated into erythrocyte
membranes in a dose-dependent and time-dependent
manner [41]. Secondly, a symptom diary will be used to
document self-reported supplementation consumption
including whether the capsules were consumed each
day, how many capsules were consumed and whether
any side effects were experienced such as eructation or
heartburn. Thirdly, participants will be asked to returnTable 2 Feasibility outcomes and key feasibility criteria
Outcome Outcome measure
Process
Recruitment rate Number of participants recruited per week.
Retention rate Number of participants completing the intervention
Supplement adherence
rate
Symptom diary.
Change in RBC total LCn-3PUFA content.
Capsule count at study completion.
Refusal rate Number of identified volunteers who decline to
participate/randomize.
Time lost to
exacerbation
Symptom diary.
Scientific
Supplement safety Reported symptoms from supplement.
Estimate effect size Listed scientific outcomes.
Estimate variance Standard deviations of listed outcomes.
CRP, C-reactive protein; FEF25-75, forced expiratory flow between 25 and 75% of forc
RBC, red blood cell.all unused capsules at the completion of the study and
the remaining capsules will be counted.
The time lost to exacerbation (change in usual symptoms
potentially leading to a change in medication, change in
usual activities or unscheduled visit to a doctor) will be de-
termined using a symptom diary in the format of one
month per page. The diary enables the assessment of ex-
acerbation frequency and severity during the supplementa-
tion period. The number of exacerbation days will be
counted from the diary, while an exacerbation severity
score will be calculated using methods adapted from those
described by Effing et al. [42]. Data collected from the
symptom diary will be used to determine the frequency of
exacerbation, whether periods of exacerbation impact upon
supplement consumption and whether periods of exacerba-
tion have a confounding effect on supplementation or study
outcomes. This information will be used to determine
whether exacerbations during the supplementation period
should be an exclusion criterion in a subsequent study.
Participant experience and perspectives will be gath-
ered using a structured telephone interview on exit from
the study. The structured interview will have four main
sections including: 1) the assessments (for example,
opinions about the test battery, use of the symptom
diary); 2) the supplement (for example, adherence,
symptoms and which arm of the trial they believed they
were on, any adverse effects experienced); 3) the trial
visits and the trial itself (for example, length of the visits,
best and worst things about participating in the trial,
participation in future trials); and 4) the participants
(for example, behavioral changes during trial and lifeKey feasibility criteria
Recruit 40 participants in 52 weeks.
. Complete the intervention in 80% of all recruited participants.
≥2% change in total RBC LCn-3PUFA.
≥80% of capsules consumed.
A positive moderate effect size (≥0.2) in at least CRP, dyspnea
and FEF25-75.
ed vital capacity ; L Cn-3PUFA, long chain omega-3 polyunsaturated fatty acid;
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outcomes).Scientific outcome measures
A number of scientific outcomes have been included in
order to determine which are the most appropriate for
use in a subsequent study. Scientific outcomes have been
selected which reflect stages in the theoretical mechan-
ism cascade from cellular (for example, inflammatory
biomarkers) to patient-centered (dyspnea, exercise cap-
acity, quality of life) outcomes. Figure 2 presents the
proposed cascade between LCn-3PUFA supplementation
and the outcome measures.
6MWD, six minute walk distance; CRQ, chronic
respiratory questionnaire; FEF25-75, forced expiratory
flow between 25 and 75% of forced vital capacity; HADS,
hospital anxiety and depression scale; IOS, impulse
oscillometry; PUFA, polyunsaturated fatty acidBlood biomarkers
Venous blood samples will be obtained after a 10 to 12-
hour overnight fast by venepuncture (EDTA-containing
tubes) and will be centrifuged within two hours of sam-
pling. Plasma will be removed and erythrocytes will be
washed with saline. Aliquots of plasma and erythrocytes
will be stored at −80°C until analysis. Relative propor-
tions of individual fatty acids in erythrocyte phospho-
lipids will be assessed using a method adapted from
previously established methods [43-45] and described in
detail by Milte et al. [46]. In this process fatty acids will
be extracted and transmethylated and the methyl esters
will be separated and quantified using a Shimadzu 2010inflammatory 
biomarkers
small airwa
(IOS and
Omega-3 PUFA
supplementation
erythrocyte 
omega-3 content
exacerbations
(frequency and severity)
Figure 2 The proposed relationship between omega-3 fatty acid suppgas chromatograph (Shimadzu, Milan, Italy). Fatty acid
methyl esters will be identified by comparing retention
times to those of authentic lipid standards (GLC-463,
Nu-Chek Prep Inc. Elysian, MN, USA). Inflammatory
biomarkers including tumor necrosis factor (TNF-α),
interleukin-1 beta (IL-1β) and interleukin-6 (IL-6) and
the anti-inflammatory biomarker interleukin-10 (IL-10)
will be analyzed in duplicate using multiplex Luminex
analyzer (Luminex B.V., Oosterhout, The Netherlands)
assays. Intra- and inter-assay coefficients of variation
(CV) are 5 to 14% and 4 to 18%, respectively. High sen-
sitivity C-reactive protein will be measured using an au-
tomated spectrophotometric analyzer (Konelab, Model
20xTi; Thermo Electron, Waltham, MA, USA); the CV
for this determination is 2.3%.Pulmonary function
Lung function tests will follow standardized American
Thoracic Society/ European Respiratory Society taskforce
guidelines [47] to determine forced expiratory volume in 1
second (FEV1), forced vital capacity (FVC), inspiratory cap-
acity (IC) and vital capacity (VC), which enables the diag-
nosis and severity classification of COPD. Small airways
function will be assessed using two methods: forced expira-
tory flow will be measured at various time points (FEF25-75,
FEF25, FEF50, FEF75) [47] and impulse oscillometry will be
used to determine respiratory impedance through the appli-
cation of small pressure oscillations at the mouth during
normal breathing [48]. Single-breath determination of car-
bon monoxide (CO) uptake will be used to determine the
gas transfer efficiency of the lung tissue as the diffusing cap-
acity of carbon monoxide (DL, CO) [49], which is reducedys function
 FEF25-75)
work of
breathing 
dyspnea
functional 
exercise 
capacity 
(6MWD)
well being 
(HADS and CRQ) 
lementation mechanisms and outcomes of interest.
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Lung volumes will be determined using body plethysmog-
raphy [50].
Dyspnea
The sensation of dyspnea is currently considered to have
three domains (sensory quality, intensity and unpleasant-
ness). The Dyspnoea-12 questionnaire will be used to
assess the sensory quality of breathlessness. Visual analogue
scales (10 cm horizontal line anchored on the left as un-
affected) will be used to quantify unpleasantness (not un-
pleasant to worst unpleasantness imaginable) and intensity
(no breathlessness to the worst possible breathlessness) of
dyspnea. Assessments of dyspnea will be conducted at rest
(average sensation over the past two weeks) and immedi-
ately after the six-minute walk test (breathlessness induced
by exercise). The mMRC score will be used to assess dys-
pnea related functional impairment, with a scoring system
of 0 to 4 (where 4 represents severe breathlessness related
impairment). The mMRC scale is widely used in people
with COPD and is a reliable (intraclass correlation = 0.82)
[51] tool with acceptable concurrent validity (r = 0.70) [52].
Functional exercise capacity
The six-minute walk test will be used to determine
change in functional exercise capacity (six-minute walk
distance). Participants walk on a hard flat surface as far
as they can in six minutes (one lap up and back = 40m),
stopping for breaks if required. The test will be conducted
twice with the maximum walk distance used for analysis.
The six-minute walk test is a reliable (CV = 8%, intra-class
correlation coefficient = 0.93) measure when conducted
under standardized conditions [53,54] and is commonly
used as an indicator of functional exercise capacity in the
COPD population [55-57] as well as other chronic diseases
such as cardiovascular disease [58].
Well-being
The Hospital Anxiety and Depression Scale (HADS), a
widely used reliable validated tool [59] will be used to
assess symptoms of depression and anxiety [60]. The
HADS has been used previously in the COPD popula-
tion with good reliability (Cronbach’s α = 0.86 (part A)
and 0.87 (part B)) [61]. The chronic respiratory ques-
tionnaire (CRQ) is a self-administered respiratory spe-
cific quality of life questionnaire with good reliability
[62] and validity [63]. The questionnaire assesses four
domains including dyspnea, fatigue, emotional function
and mastery [62].
Data analysis
SPSS version 17 for WINDOWS [International Busi-
ness Machines Corporation (IBM), New York, USA]
will be used for analyses. Data will be cleaned,checking for errors or missing values. Continuous data
will be checked for normality of distribution and non-
normally distributed data will be transformed where
possible. Scatter plots will be used to determine
nature/shape of relationships before applying linear
regression.
The primary focus of this study is feasibility, which
will be analyzed using descriptive statistics and fre-
quency tables. The key feasibility outcomes are:
1. Recruit 40 participants in 52 weeks;
2. Complete the intervention in 75% of all recruited
participants;
3. ≥2% change in total erythrocyte LCn-3PUFA and
≥80% of capsules consumed (estimated from
remaining capsules);
4. A positive moderate effect size (≥0.2) in at least
three scientific outcome measures (between active
and placebo groups).
Analysis of variance (ANOVA) with repeated measures
will be used to estimate the effect size of LCn-3PUFA
versus placebo supplementation on the scientific out-
come measures (six-minute walk, pulmonary function
tests, questionnaire scores, blood biomarkers of inflam-
mation and symptoms (for example, high sensitivity
C-reactive protein, dyspnea and impulse oscillometry)).
Progressive Bonferroni corrections will be used to cor-
rect for the effects of multiple outcomes. Comorbid sta-
tus and severity of exacerbations will be assessed as
potential confounders using multiple regression analysis.Assessment administration
All measures will be completed in the respiratory medi-
cine laboratory at the RGH, and will be administered by
the same investigator (AF, excluding lung volumes and
gas transfer), which will be conducted by respiratory
function scientists). The testing sessions will last ap-
proximately two hours. Tests will be conducted in the
following order: blood collection, pre-bronchodilator
spirometry, gas transfer (administration of bronchodila-
tor prior to), lung volume, first six-minute walk, ques-
tionnaires, post bronchodilator spirometry and the
second walk test. All assessments will be timed and
compared to the estimated completion time as a feasibil-
ity outcome. All blood analysis including preparation
(saline wash) will be conducted by the same investigator
(AF, excluding Luminex analysis, for which AF will assist
a NPRC staff member). Initial preparation of samples
will occur at the SA Pathology laboratory at the RGH,
and all analyses (erythrocyte fatty acid extraction and
biomarker analysis) will occur in the NPRC laboratory
(AF and other NPRC laboratory staff ).
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People with COPD have an accumulation of inflamma-
tory cells in the respiratory tissue that causes damage to
the lungs [64]. This is further compounded by the effects
of systemic inflammation such as reduced muscle func-
tion and skeletal integrity, which are often associated
with comorbidities such as cardiovascular disease and
osteoporosis [5-7]. The anti-inflammatory properties of
LCn-3PUFA have been beneficial in other inflammatory
diseases with recent systematic reviews in rheumatoid
arthritis and cardiovascular disease concluding that the
benefits of LCn-3PUFA are modest but clinically
relevant [65,66]. In people with rheumatoid arthritis all
included studies showed some clinical benefit with LCn-
3PUFA supplementation [66], while in cardiovascular
disease those supplemented with LCn-3PUFA had a 10%
reduction in the number of cardiovascular events [65].
Given the impact of lung and systemic inflammation,
dietary supplementation with LCn-3PUFA may be
beneficial for people with COPD.
The current evidence for benefits of LCn-3PUFA in
people with COPD is limited; there has been one RCT,
although not exclusively using LCn-3PUFA. The major-
ity of studies focus on the association between self-
reported intakes of LCn-3PUFA and prevalence of
COPD (Table 1). Most of these studies used spirometry
to diagnose COPD; however, the definition of COPD
(Global initiative for chronic obstructive pulmonary
disease (GOLD) stage [1]) or spirometric criterion varied
between studies. Shahar et al. [18] and McKeever et al.
[17] did not use post-bronchodilator spirometry in the
diagnosis of COPD, and therefore irreversible airflow
limitation (a requirement of COPD) could not be
confirmed.
The RCT conducted by Broekhuizen et al. [14] did not
test effects of LCn-3PUFA specifically; it was combined
with other PUFAs. Hence it is unclear whether LCn-
3PUFA alone was responsible for the observed changes
in outcomes or whether these changes were attributable
to the combinations of nutrients. The dose of LCn-
3PUFA (EPA and DHA) used in the Brekhuizen et al.
[14] study was approximately 1 g/day for eight weeks. It
is suggested by Calder [67] that a minimum dose of 2 g/
day is required to elicit the anti-inflammatory properties
of omega-3 fatty acids (DHA + EPA). This study com-
bined supplementation with pulmonary rehabilitation,
the beneficial effects of which are well documented in
people with COPD [68]. Broekhuizen et al. [14] suggests
that the increases in exercise capacity could be a result
of increased fatty acid availability and oxidative capacity
which could be related to changes in muscle fiber type
through exercise. Pulmonary rehabilitation may have fa-
cilitated the reported effects of PUFAs in COPD; how-
ever the effects of PUFA supplementation alone onhealth outcomes in people with COPD are still unknown
and warrant investigation.
The proposed study aims to determine not only the
feasibility of the study protocol but also which outcomes
might be appropriate to include in a larger trial. In order
to achieve these aims, a number of outcomes have been
included, ranging from cellular, such as blood bio-
markers of inflammation, to patient centered measures,
such as dyspnea and exercise capacity. While there are
likely to be changes in cellular outcomes such as inflam-
matory biomarkers, it is possible that a corresponding
change in clinically relevant outcomes such as dyspnea
may not be achieved. This is likely to influence uptake of
LCn-3PUFA supplementation by people with COPD and
health care practitioners as a worthwhile addition to
current best practice.
Studies in fish oil supplementation have previously
shown good adherence with the supplementation proto-
col [41]. Adherence in people with COPD is likely to be
similar to that shown in previous studies; however, exac-
erbations are common in this population and depending
on the severity, may lead to changes in medication and
hospitalization during the supplementation period. Dur-
ing these periods of time supplementation adherence
may be affected. A number of other factors may also
influence adherence, such as comorbidities (notably anx-
iety and depression) and multiple medications associated
with the COPD and/or the comorbidities. The dose and
duration of supplementation in the current protocol is
similar to that used in other studies of fish oil and
chronic inflammatory conditions (for example, rheuma-
toid arthritis). However, as suggested above, it is possible
that COPD patients may find it challenging to consume
their usual medications plus fish oil capsules. By provid-
ing concentrated capsules containing more (600 mg/g)
of the active fatty acids and lesser of unnecessary fat, we
expect improved compliance as this reduces the number
of capsules required to achieve the desired dose.
Pilot and feasibility studies are often disregarded and
overlooked within the literature but have the potential
to provide valuable information [27]. For example, at the
completion of a pilot or feasibility study, reporting the
‘challenges faced’ has the potential to assist other re-
searchers in trial design [27]. Crucially the pilot or feasi-
bility trial will provide information about a population
that is not currently available such as ease (or difficulty)
in recruitment, and it may also highlight issues with the
study protocol not evident during the planning phase.
These issues could be crucial to the success or failure of
a large study.
In summary, while LCn-3PUFA supplementation in
people with COPD may be beneficial there are a number
of unknown factors such as supplement adherence, ap-
propriate sample size and choice of outcome measures.
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the study and to provide data to guide the design of fu-
ture studies in dietary supplementation studies in people
with COPD.
Trial status
Not yet recruiting.
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